MD, PhD. Postdoc at Aarhus University / Dept. of Cardiology, Aarhus University Hospital, Denmark. Investigating image-based coronary physiology @FAVORIIITrial
Aarhus, Denmark
Joined July 2013
- Tweets23
- Following67
- Followers124
- Likes49
Birgitte Krogsgaard retweeted
Coronary revascularisation deferral based on QFR or FFR: a post-hoc analysis 🔎 of the FAVOR III Europe trial
@drgocchipinti & @sbrugaletta review ✍️ this analysis that found that QFR-based deferral of coronary artery revascularisation resulted in a higher incidence of 1-year MACE as compared with FFR-based deferral.
pcronline.com/PCR-Publicatio…
#EAPCI #JournalClub #interventionalcardiology
Birgitte Krogsgaard retweeted
Deferred Revascularization Safer When Guided by FFR vs QFR: FAVOR III Europe dlvr.it/THGVYB
Important insights from the @FAVORIIITrial . Despite a 21% increase in PCI rate when using QFR, the occurrence of MACE was higher following revascularisation deferral by QFR than by FFR. @JEscaned @NielsRHolm @h_evald
❌NEW AHEAD OF PRINT❌
"Coronary revascularisation deferral based on quantitative flow ratio or fractional flow reserve: a post hoc analysis of the FAVOR III Europe trial" @JEscaned
#Cardiology #CoronaryArteryDisease #PCI #ClinicalResearch
Read the full article: ow.ly/kBZz50UyOIU
A great summary of the findings in the @FAVORIIITrial by @TCTMD, with important comments by @mmamas1973 and @JoostDaemen
Several substudies in the pipeline - hopefully adding further insights soon.
#TCT2024 #QFR #RCT #CardioTwitter
Birgitte Krogsgaard retweeted
Congratulations @NielsRHolm and @B_Krogsgaard for delivering the FAVOR III Europe Trial. Honored to provide the commentary for this presentation
@mirvatalasnag @dr_benoy_n_shah @drptca @NickCurzen @drandrewsharp @purviparwani @iamritu @hvanspall @JGrapsa @jgranadacrf
1/x #QFR did not meet non-inferiority to FFR in the @FAVORIIITrial Europe presented by @B_Krogsgaard The 1-year primary EP of death, MI, and unplanned revasc was 6.7% vs 4.2% in favour of FFR. 21% more study-lesions were treated- and 27% more stents were implanted with QFR due to a lower median QFR of 0.81 vs 0.84 for FFR. Published online in The Lancet.
@h_evald @WestraJelmer @DrKoltowski @Eric_Van_Belle @GianlucaCampo78 @SimoneBiscaglia @ThueOlsen @AshkanEftekhar1 @ignamatsant @BarbaraStahli @ramonlopezpalop @HelleBargsteen @JEscaned @mirvatalasnag @mmamas1973 @HernanDMejiaR #TCT2024 #cardiotwitter #randomizedtrial
Birgitte Krogsgaard retweeted
FAVOR III Europe trial results are in! 🌍 QFR-based strategy in coronary physiology doesn’t match FFR for clinical outcomes at one year. Findings announced at #TCT2024 and published in @TheLancet.
thelancet.com/journals/lance…
#CardioX #CardioTwitter #CardioEd #CardioResearch @BurkhoffMd @djc795 @georgedangas @jgranadacrf @MartyBLeon @MaeharaAkiko @Drroxmehran @sahilparikhmd @triciarawh @TCTConference @jedicath @Dr_ibrahimHarbi @Almanfi_Cardio @BakhshiHooman @ABeneduceMD @nyalborgesmd @aayshacader @BCase07 @NishithChandra @baileyannRN @fischman_david @hect2701 @JGrapsa @HamidNadira @stefan_harb @AmandaLimaMD @evandrofilhobr @GiorgioMedranda @mornei2011 @SrihariNaiduMD @sumonroy_md @DocSavageTJU @Shoaib9702 @poojaotherwise @iamritu @atunuguntla1 @Pooh_Velagapudi @EZancanaroMD @AdrianaCMares @NielsRHolm @IAmDoctorAbhi @KrutarthKPandya @IndahSP_MD @ShariqShamimMD @mirvatalasnag
I am proud of our team work in both conducting and reporting the @FAVORIIITrial. Publication is now available online in @TheLancet
@NielsRHolm @h_evald
Presented today at #TCT2024:
Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial hubs.li/Q02W6crZ0 @TCTConference
ALT Research in context panel. Copyright: 2024 Elsevier Ltd. All rights reserved.
Birgitte Krogsgaard retweeted
#QFR is NOT non-inferior to #FFR. Findings from the @FAVORIIITrial at #TCT2024
@AUHCardio @NielsRHolm @B_Krogsgaard @h_evald
Birgitte Krogsgaard retweeted
Angio derived Quantitative Flow Reserve inferior to wire based FFR in FAVOR 3. #TCT2024 View it here: clinicaltrialresults.org/wp-…
Birgitte Krogsgaard retweeted
1/x #QFR did not meet non-inferiority to FFR in the @FAVORIIITrial Europe presented by @B_Krogsgaard The 1-year primary EP of death, MI, and unplanned revasc was 6.7% vs 4.2% in favour of FFR. 21% more study-lesions were treated- and 27% more stents were implanted with QFR due to a lower median QFR of 0.81 vs 0.84 for FFR. Published online in The Lancet.
@h_evald @WestraJelmer @DrKoltowski @Eric_Van_Belle @GianlucaCampo78 @SimoneBiscaglia @ThueOlsen @AshkanEftekhar1 @ignamatsant @BarbaraStahli @ramonlopezpalop @HelleBargsteen @JEscaned @mirvatalasnag @mmamas1973 @HernanDMejiaR #TCT2024 #cardiotwitter #randomizedtrial
Birgitte Krogsgaard retweeted
Get ready to witness groundbreaking data @ #TCT2024! In collaboration with @JAMA_current this session features:
✨TRISCEND II
✨ACURATE IDE
✨FAVOR III Europe
✨FLASH
@arnoldgehrke @SusheelKodaliMD @MReardon19 @NielsRHolm @wfearonmd @npfam1 @LindaGillamMD @jgranadacrf @mmamas1973
Birgitte Krogsgaard retweeted
It’s late breaking day!
Watch @B_Krogsgaard from @AUHCardio presenting the main results of FAVOR III Europe at #TCT2024
It is 11:47 AM at main arena!
Watch it online here:
crfconnect.com/conference/tc…
Birgitte Krogsgaard retweeted
@TCTMD Interview with @B_Krogsgaard @wfearonmd and @mmamas1973 on the @FAVORIIITrial - LBT presentation #TCT2024 Wednesday at 11:47 EST - Details in the simultaneous publication #coronaryphysiology #randomizedtrial #cardiotwitter
Birgitte Krogsgaard retweeted
@FAVORIIITrial on QFR vs FFR to be presented as LBT 30. October at #TCT2024 - Methods paper here: eurointervention.pcronline.c…
Birgitte Krogsgaard retweeted
Primary endpoint of the @FAVORIIITrial on QFR vs. FFR is presented on 30. October at #TCT2024
#qfr #randomizedtrial #cardiotwitter
@B_Krogsgaard @h_evald @JEscaned @GianlucaCampo78 @DrKoltowski @gret_ziu @SejrHansen @ignamatsant @BarbaraStahli @HernanDMejiaR @llddss80 @WestraJelmer @ramonlopezpalop @ThueOlsen @SimoneBiscaglia
#TCT2024 Late-Breaking Research Announced! 🚨
🌟 The moment you’ve been waiting for is here! Discover game-changing research that will revolutionize cardiovascular care. Get ready to witness the breakthroughs that will transform your practice and redefine patient outcomes. 🚀 tct2024.crfconferences.com/l…
Secure your spot now! 👉 tct2024.crfconferences.com/r…
#CardioX #CardioTwitter #CardioEd #CardioResearch @BurkhoffMd @djc795 @georgedangas @jgranadacrf @MartyBLeon @Drroxmehran @sahilparikhmd @triciarawh @TCTConference
Birgitte Krogsgaard retweeted
Yesterday, prof. @GianlucaCampo78 and his team in Ferrara enrolled patient no 1000 in the @FAVORIIITrial. Ferrara is also the top enrolling center followed by Sahlgenska, Sweden and Clinique Axium, Aix-en-Provence, France. @SimoneBiscaglia @Tebaldi_Matteo @NielsRHolm
Birgitte Krogsgaard retweeted
This morning, we reached a major milestone in the FAVOR III trial! Patient number 500 was enrolled by dr. Hernán Mejía-Renteria and his colleagues at Hospital Clinico San Carlos, Madrid. Beyond grateful for the collaboration! #QFR @NielsRHolm @h_evald @B_Krogsgaard @HernanDMejiaR
Birgitte Krogsgaard retweeted
POST-PCI FUNCTIONAL ASSESSMENT - new comprehensive review @WijnsWilliam @djc795 @WestraJelmer @NielsRHolm academic.oup.com/eurheartj/a…
